

ASTRAZENECA PLC

Interim financial statements

30 SEPTEMBER 2004

Registered number : 2723534



ASTRAZENECA PLC

PROFIT AND LOSS ACCOUNT for the period ended 30 Sept 2004

	Notes	30 Sept 2004 \$m	31 December 2003 \$m
Turnover		-	-
Operating costs		-	(5)
Operating loss		-	(5)
Income from shares in subsidiary undertakings		-	-
Profit on ordinary activities before interest		-	(5)
Net interest and exchange gains/(losses)	2	269	354
Profit on ordinary activities before taxation		269	349
Taxation		(5)	(105)
Net profit for the year		264	244
Dividends to Shareholders	3	(494)	(1,350)
(Loss) retained for the period		(230)	(1,106)

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES for the period ended 30 Sept 2004

Apart from the gains and losses reported above, the Company has recorded a gain of \$282m in respect of the tax settlement of an unrealised exchange loss.

ASTRAZENECA PLC


BALANCE SHEET

as at 30 Sept 2004


	Notes	30 Sept 2004 \$m	31 December 2003 \$m
Fixed Assets			
Tangible fixed assets		-	-
Fixed asset investments	4	7,744	6,940
		7,744	6,940
Current assets			
External debtors – Other		161	7
Debtors – amounts owed by subsidiaries		23,253	25,339
Cash and short-term investments		-	-
		23,414	25,346
Total assets		31,158	32,286
Creditors due within one year			
Short-term borrowings		(6)	(3)
Other Creditors		(16)	(1,068)
Amounts owed to subsidiaries		(2,659)	(2,049)
		(2,681)	(3,120)
Net current assets		(20,733)	22,226
Total assets less current liabilities		28,477	29,166
Creditors due after more than one year			
Loans		(1,029)	(295)
		(1,029)	(295)
Provisions for liabilities and charges		-	-
Net Assets		27,448	28,871
Capital and reserves			
Called-up share capital	5	415	423
Share premium account	6	524	449
Capital redemption reserve	6	31	23
Other reserves	6	1,841	1,841
Profit and loss account	6	24,637	26,135
Shareholders' fund – equity interests		27,448	28,871

The financial statements on pages 1 to 5 were approved by the Board of Directors on 16 December 2004 and were signed on its behalf by :

Sir Tom McKillop, Director



Jonathan Symonds, Director



ASTRAZENECA PLC

NOTES RELATING TO THE INTERIM FINANCIAL STATEMENTS

1 Basis of presentation of financial information

The AstraZeneca PLC interim financial statements are presented in accordance with the accounting policies set out in the 2003 annual accounts.

2 Net interest and exchange gains/(losses)

	30 Sept 2004 \$m	31 Dec 2003 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(17)	(30)
External interest payable	(14)	-
Net exchange gains/(losses)	31	28
	-	(2)
Interest receivable and similar income		
Receivable from subsidiary undertakings	269	356
	269	356
Net interest and exchange gains/(losses)	269	354

NOTES RELATING TO THE INTERIM FINANCIAL STATEMENTS (continued)

3 Dividends to Shareholders

	2004 cents per 25c Share	2003 cents per 25c Share	30 Sept 2004 \$m	31 Dec 2003 \$m
1 st interim	29.5	25.5c	494	436
2 nd interim/final	-	54.0c	-	914
	29.5	79.5c	494	1,350

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost or valuation			
At beginning of period	6,645	295	6,940
Additions	70	747	817
Disposals and other movements	-	(13)	(13)
Cost or valuation and net book value at end of period	6,715	1,029	7,744

5 Called-up share capital

	Authorised 2004 \$m	Allotted, called-up and fully paid	
		2004 \$m	2003 \$m
Ordinary Shares (\$0.25 each)	415	415	423
Unissued Ordinary Share (\$0.25 each)	185	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	415	423

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,693	423
Issue of shares	2	-
Repurchase of shares	(34)	(8)
At 30 September 2004	1,661	415

NOTES RELATING TO THE INTERIM FINANCIAL STATEMENTS (continued)

6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 30 Sept 2004 \$m	Total 31 Dec 2003 \$m
At beginning of period	449	23	1,841	26,135	28,448	30,655
Net gains for the period	-	-	-	546	546	244
Dividends	-	-	-	(494)	(494)	(1,350)
Share repurchase	-	8	-	(1,550)	(1,542)	(1,147)
Share premiums	75	-	-	-	75	46
At end of period	524	31	1,841	24,637	27,033	28,448
Distributable reserves at end of period	-	-	564	1,714	2,278	1,592

At 30 Sept 2004 \$22,923m (31 December 2003 : \$25,032 m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During 2004 \$ 2,109m of the profit was realised by repayment. Subsequent to the period end AZ Plc sold tax losses to a subsidiary resulting in \$505m distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

7 Reconciliation of Movements in Shareholders' Funds

	30 Sept 2004 \$m	31 Dec 2003 \$m
Net gains for the period	546	244
Dividends	(494)	(1,350)
	52	(1,106)
Issues of AstraZeneca Ordinary Shares	75	47
Repurchase of AstraZeneca Ordinary Shares	(1,550)	(1,154)
Net reduction to shareholders' funds	(1,423)	(2,213)
Shareholders' funds at beginning of period	28,871	31,084
Shareholders' funds at end of period	27,448	28,871